Back to search

Aristotle University Of Thessaloniki (AUTH)

Η επίδραση της θεραπείας με βαλπροϊκό νάτριο στο δείκτη μάζας σώματος παιδιών προεφηβικής ηλικίας με επιληψία

Abstract

dc:description

Valproic acid (VPA) is an antiepileptic drug that is extensively used for treatment of a variety of seizure types in childhood epilepsy. It is well established that VPA treatment is frequently associated with extensive weight gain in children with epilepsy. The pathogenetic mechanism by which VPA can induce weight gain is still not clarified. Several hypothetic mechanisms have been implicated to explain the effect of VPA on the regulation of energy balance: Increased appetite and low blood glucose level, hyperinsulinemia, hyperleptinemia, increased levels of ghrelin, dysregulation of the hypothalamic system etc.The aim of this study was : a) to evaluate the effect of VPA monotherapy on body mass index of prepubertal children with generalized idiopathic epilepsy and b) to evaluate probable effect of VPA on blood insulin, leptin, ghrelin, peptide YY3-36, glucose and lipid levels of patients.A total of 26 prepubertal patients, 14 females and 12 males, mean aged 7 ± 2,63 years were enrolled in this study. All children were newly diagnosed as epileptic after the second episode of unprovoked epileptic seizures. All patients were diagnosed as idiopathic generalized epilepsy and initiate valproate monotherapy at starting dose 10 mg/kg and subsequent titration until optimal clinical response. Maintenance dosage didn’t exceed 30 mg/kg. The seizures were completely controlled in all patients from the first month of antiepileptic therapy.Patients known to suffer from chronic diseases such as cardiopathy, nephropathy, hepatopathy, endocrinopathy, delayed psychomotor development and cerebral palsy were excluded from the study. Moreover, patients known to use or have previous use of drugs that can affect calorie intake were not included in the study.Control healthy subjects comprised of 26 children, 14 girls and 12 boys, were also enrolled in the study. The mean age of children of the control group was 6,92 ± 2,63 years. All control subjects were healthy members of the families of children that are outpatients of the developmental center “A. Fokas”, first department of Paediatrics, Aristotle University of Thessaloniki. From the control group were excluded children with chronic diseases of liver, kidneys and heart, children with endocrinopathy, infectious diseases or BMI≥95 percentile curve.Study protocol: All patients were clinically examined and puberty stage was assessed according to Tanner. Bone age was evaluated, by the method of Greylich and Pyle based on a radiograph of the left hand and wrist, at the initiation of the study. Brain magnetic resonance was performed at baseline time t0. All patients were prepubertal, had normal physical examination, normal brain MRI findings and bone age consistant with chronological age. of therapy with VPA. Fasting serum insulin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, insulin, leptin, ghrelin, peptide YY3-36 were obtained at baseline t0 and after 12 months of therapy. Serum valproate levels were also measured at t12.Concerning the control group, body weight, height, and waist circumference of each child were evaluated and BMI was calculated as weight (kg) divided to square height (m2). Assesment of body weight, height and BMI percentiles were done according to the development curves of the A’ Pediatric Department of the university of Athens, applied to Greek population. All measurements were done at the beginning of the study and after 12 months. Z-scores of body weight, height and BMI were calculated at baseline and after 12 months also.The VPA-treated patients had significantly increased weight-Z-score(p=0,001) and Z-score BMI (p=0,026) and waist circumference(p<0,001) at time t12. We didn’t notice any significant difference between the patients and the control group concerning the Z score BMI, weight- Z- score and waist circumference at t0 or t12. Among the VPA-treated patients 2 boys were overweight and 2 other boys were obese at baseline t0 evaluation. These four patients remain overweight and obese respectively at the time t12. Among the 26 patients, 3 girls (11,5%) who had normal BMI at time t0 become overweight at time t12.Serum fasting glucose, total cholesterol, HDL cholesterol and LDL cholesterol levels were not significantly changed at 12 month of therapy. A significant decrease (p=0,044) in serum triglyceride level was noticed at t12 time.Serum insulin, leptin, ghrelin and peptide YY3-36 levels were significantly (p=0.015, p<0,001, p=0.016, p=0.003) increased at the end of the study, 12 months after the initiation of VPA therapy. Two patients (7,7%) develop insulin resistance and hyperinsulinemia at time t12.We evaluate several correlations between the anthropometric and the laboratory parameters of our study. The most interesting results were the positive correlation between insulin and leptin levels at time t0 and t12(p=0.033,p=0.019), and the negative correlation between the change of leptin and the change of ghrelin (p=0.044). No correlation was found between the serum valproate levels and serum levels of glucose, lipids, insulin, leptin, ghrelin and peptide YY3-36. No correlation was reported between the sex of the patient and the levels of serum insulin, leptin, ghrelin and peptide YY3-36.There was no statistical difference between the BMI of male and female patients at t12 time.In conclusion, in our study, prepubertal VPA-treated patients demonstrate a significant increase in weight gain after 12 months of therapy. However, although they gain weight, none of them became obese at the t12 time evaluation. The significant increase that we notice at the levels of insulin, leptin, ghrelin and peptide YY3-36 may be the result of a complicated and multifactorial mechanism by which valproic acid causes obesity.A longer follow-up period and more studies are required in order to clearly demonstrate the way by which VPA affects body weight.The combination of increased body weight and increased waist circumference with hyperinsulinemia makes the VPA-treated patient more susceptible to the risk of the metabolic syndrome. It is important, for the clinician, to evaluate regularly the parameters of body weight, BMI and waist circumference of each patient treated with valproic acid, in order to have the chance to protect his patients through early intervention.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Theodoni, Georgia
  • Θεοδώνη, Γεωργία

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35955

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Theodoni, Georgia; Θεοδώνη, Γεωργία. Η επίδραση της θεραπείας με βαλπροϊκό νάτριο στο δείκτη μάζας σώματος παιδιών προεφηβικής ηλικίας με επιληψία. Aristotle University Of Thessaloniki (AUTH), 2015. http://hdl.handle.net/10442/hedi/35955